Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Rituximab (RTX), a chimeric anti‐CD20 antibody, is associated with direct induction of apoptosis and antibody‐dependent cell‐mediated cytotoxicity (ADCC) with clinical efficacy in mantle cell lymphoma (MCL). Lenalidomide (LEN), a novel immunomodulatory agent, sensitizes tumor cells and enhances ADCC. Our study attempted to elucidate the mechanism of LEN‐enhanced RTX‐mediated cytotoxicity of MCL cells. We found that LEN and RTX induced growth inhibition of both cultured and fresh primary MCL cells. LEN enhanced RTX‐induced apoptosis via upregulating phosphorylation of c‐Jun N‐terminal protein kinases (JNK), Bcl‐2, Bad; increasing release of cytochrome‐c; enhancing activation of caspase‐3, ‐8, ‐9 and cleavage of PARP. Meanwhile, LEN activated NK cells and increased CD16 expression on CD56 low CD16+ NK cells. Whole PBMCs but not NK cell‐depleted PBMCs treated with LEN augmented 30% of RTX‐dependent cytotoxicity. Daily treatment with LEN increased NK cells by 10‐folds in SCID mice, and combination of LEN and RTX decreased tumor burden and prolonged survival of MCL‐bearing SCID mice. Taken together, our study demonstrates that LEN plus RTX provides a synergistically therapeutic effect on MCL cells by enhancing apoptosis and RTX‐dependent NK cell‐mediated cytotoxicity and may be an optimal combination in the clinical trial of relapsed or refractory MCL. Am. J. Hematol. 2009. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237 · cited 1×
“To elucidate the upstream proteins of the caspase-dependent apoptotic pathway, we studied the effect of LEN and RTX on Bcl-2 family members and their upstream regulator JNK, which mediates signaling to members of the Bcl-2 family and inactivates the anti-apoptotic protein Bcl-2 by inducing Bcl-2 phosphorylation [22,23…”
BackgroundFunctions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943 · cited 1×
“They express the low-affinity Fcg receptor CD16 (FcgRIIIa), which enables recognition of antibody-coated target cells and induces ADCC and cytokine production [25,26].”
BackgroundInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“RTX mediates ADCC by targeting CD20 on lymphoma cells [15].”
Background
Cited by
Mechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 467
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., Casasnovas, R.-O., Flinn, I. W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805104 · Cited by 373
“Peripheral neuropathy 35 (7) 1 (<1) 79 (16) 3 (<1)”
Nowakowski, G. S., LaPlant, B., Macon, W. R., Reeder, C. B., Foran, J. M., Nelson, G. D., Thompson, C. A., Rivera, C. E., Inwards, D. J., Micallef, I. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5714 · Cited by 359
Goy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
Self-citationWang, M., Fayad, L., Wagner-Bartak, N., Zhang, L., Hagemeister, F., Neelapu, S. S., Samaniego, F., McLaughlin, P., Fanale, M., Younes, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70200-0 · Cited by 297
Self-citationMechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma
Gribben, J. G., Fowler, N., & Morschhauser, F. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5363 · Cited by 296
Fowler, N. H., Davis, R. E., Rawal, S., Nastoupil, L., Hagemeister, F. B., McLaughlin, P., Kwak, L. W., Romaguera, J. E., Fanale, M. A., Fayad, L. E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70455-3 · Cited by 264
Self-citationLenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Ruan, J., Martin, P., Shah, B., Schuster, S. J., Smith, S. M., Furman, R. R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505237 · Cited by 236
Ishida, T., Fujiwara, H., Nosaka, K., Taira, N., Abe, Y., Imaizumi, Y., Moriuchi, Y., Jo, T., Ishizawa, K., Tobinai, K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.7732 · Cited by 152
Metadata
- Authors
- Zhang, L., Qian, Z., Cai, Z., Sun, L., Wang, H., Bartlett, J. B., Yi, Q., & Wang, M.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2009-08-25
- Volume
- 84
- Issue
- 9
- Pages
- 553-559
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2000302977
- Cited by
- 147
- References
- 3
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.